Details of the Drug
General Information of Drug (ID: DM2SNR0)
Drug Name |
1-(3-Fluoro-phenyl)-piperazine
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
1-(3-Fluorophenyl)piperazine; 3801-89-6; 1-(3-Fluoro-phenyl)-piperazine; Piperazine, 1-(3-fluorophenyl)-; 1-(3-fluorophenyl)-piperazine; CHEMBL269784; Piperazine,1-(3-fluorophenyl)-; EINECS 223-271-9; AC1Q4NBT; 3-fluorophenyl piperazine; (3-fluorophenyl)piperazine; AC1L2T0A; 4-(3-fluorophenyl)piperazine; N-(3-Fluorophenyl)piperazine; SCHEMBL315894; CTK4H9144; DTXSID40191426; MolPort-000-155-895; KIFCSMQTGWVMOD-UHFFFAOYSA-N; ZINC2529848; SBB089693; ANW-61692; 4877AB; BDBM50017455; AKOS000101159; FS-1513; KB-85106; AS-10296
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 180.22 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 1.2 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||